Nov24 Regulatory approaches

Information about Nov24 Regulatory approaches

Published on April 16, 2008

Author: Alien

Source: authorstream.com

Content

PRIORITY MEDICINES FOR EUROPE AND THE WORLD :  PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and Saloni Tanna Marjolein Willemen Eduardo Sabaté Monique Renevier Joyce Wilson Lisa Greenough Ann Wilberforce Kathy Hurst Objectives of Priority Medicines Project:  Objectives of Priority Medicines Project Provide a methodology for identifying pharmaceutical “gaps” from a public health perspective, for Europe and the World . Provide a public-health based pharmaceutical R&D agenda for use by the EU in the 7th Framework Programme, “Good public policy should spend public funds on areas of greatest public needs” Generating a Preliminary List of Diseases and Gaps:  Generating a Preliminary List of Diseases and Gaps Pharmaceutical "Gap":  Pharmaceutical "Gap" Example of an absent pharmaceutical gap:  Example of an absent pharmaceutical gap "Commonality of interest" :  "Commonality of interest" Special Needs for Women, Children, and the Elderly:  Special Needs for Women, Children, and the Elderly All groups neglected in drug development Complicated by different physiology & metabolism Recent improvements in situation of women and children Considerable gaps remain for the elderly who use the most medicines Promoting Innovation and Removing Barriers:  Promoting Innovation and Removing Barriers Public Private Partnerships may be a vehicle to address market failure Pricing issues are critical to the future of the European pharmaceutical industry. Propose investigating differential pricing based on GNI per capita and efficacy measures. Reseach prospective price setting. EMEA, FDA, Rawlins and Industry have all proposed similar measures to remove barriers Comparative trials provide critical information on head to head comparisons. Use of European databases may facilitate such studies Differential Pricing: Indicative prices in US$/annum of highly active antiretrovirals (HAART) and a new hypothetical regimen in countries of variable wealth :  Differential Pricing: Indicative prices in US$/annum of highly active antiretrovirals (HAART) and a new hypothetical regimen in countries of variable wealth Barriers to Innovation: Background:  Barriers to Innovation: Background Cost and duration of medicines development have increased Many projects in early development stages, but not enough of this potential innovation is being translated into market approvals. For some diseases, there remains an inadequate understanding of basic science, and potential targets for medicines development have not been identified. Recent Publications:  Recent Publications Four papers published almost simultaneously, plus commentary on Priority Medicines website EMEA: Discussion Paper: The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future  FDA: " Challenge and Opportunity on the Critical Path to New Medical Products" Perspectives – "Cutting the Cost of Drug Development?" M.D. Rawlins Sue Middleton: GSK Commentary on "Barriers to Innovation" Barriers to Innovation: Suggested Solutions:  Barriers to Innovation: Suggested Solutions All authors agreed that every aspect of the regulatory process should be re-examined and that the evidence base for regulatory practices should be critically analysed using modern methodologies. Preclinical studies Many old tests and methods New analytic tools needed Validation of old methods required Clinical Studies Regulatory authorities are risk averse so the RCT has become the gold standard Other approaches even using historical controls may be possible and desirable Neglected Areas: Post marketing Surveillance and Patients:  Neglected Areas: Post marketing Surveillance and Patients All papers neglect Phase IV studies as a part of the innovation process. Great opportunities for Europe from use of electronic data bases for Phase IV studies on both efficacy and safety Apart from the industry paper, none of the three other papers mention any role for patients in this review. They are referred to as beneficiaries of the process but never as contributors to the decision-making. Role of Patients remains unclear:  Role of Patients remains unclear Patients have speeded innovation e.g. AIDS and Orphan diseases Valuable role in treatment guideline development emerging e.g. NICE Patients play important role in ethical & hospital committees e.g. IRB & DTCs Will now be part of CSM in UK Future role likely to be important and growing A "barriers to innovation" Research Agenda:  A "barriers to innovation" Research Agenda Bottlenecks and barriers in the current medicines development process are to be identified and solutions elaborated to overcome them. Range of stakeholders required: academia, clinicians, patient organizations, large and small industry, regulatory and ethics specialists Every requirement within the medicines development process whether clinical or preclinical should be questioned for its regulatory relevance, costing, and predictive value. The involvement of the EMEA and the various European national regulatory agencies and their scientists is critical to this initiative. 6th Framework already has issued a call closing November 16th PRIORITY MEDICINES FOR EUROPE AND THE WORLD :  PRIORITY MEDICINES FOR EUROPE AND THE WORLD Comparative Clinical Trials Chapter 8.4 Warren Kaplan Comparative Trials: Background:  Comparative Trials: Background For most medications at launch, we know little about whether or not a given medication is better value for the money than alternatives. This knowledge gap exists because most drug regulatory authorities do not examine "value for money" For most medications at launch, clinical trials are not designed to look at whether or not a given medication is better than another drug. Typically, efficacy is measured versus a control which is often, but not invariably, a placebo lacking any active ingredient. Many registration authorities do require comparative benefit studies To estimate comparative benefit between two medicines, large (time consuming and expensive) trials are needed since there are often small differences between treatment outcomes when comparing the interventions. Comparative Trials: Who should pay for them and who conducts them?:  Comparative Trials: Who should pay for them and who conducts them? Industry? Government? Or… Private insurers and the government could set aside some fraction of their annual medicines spending to endow an organization to provide an independent source of reputable research into comparative effectiveness and cost. Electronic prescription and medical databases to conduct Phase IV and/or pharmacoepidemiologic studies in place of controlled, comparative clinical trials. EU has a great comparative advantage over the USA as this kind of electronic linkage of prescribers and medical records is still fragmented in the USA Phase IV studies could add a randomization step ("randomized epidemiology") Comparative Trials/ Comparative Effectiveness:  Comparative Trials/ Comparative Effectiveness Europe 2005: "An information society for all", available at http://europa.eu.int/information_society/eeurope/2002/news_library/documents/eeurope2005/eeurope2005_en.pdf. This Action plan on "electronic health" should be used as a way of creating post-marketing studies to better understand comparative effectiveness and cost-effectiveness. General Conclusions:  General Conclusions Commonality of interest exists for chronic diseases between Europe and the World Priorities can be set based on evidence, trends and projections and social solidarity Pharmaceutical gaps exist as a result of biological challenges and market failure Highest priorities are antibacterial resistance, influenza, smoking and neglected diseases Pricing issues and barriers to innovation strongly affect the European industry The EU needs to find a way to support translational research for market failure pharmaceutical gaps Regulatory Conclusions:  Regulatory Conclusions Common view as to how regulatory obstacles serve as a barrier to innovation Different solutions proposed by different stakeholders. All should be considered Striking lack of attention to Phase 4 activities. Vioxx and FDA hearings may change everything Strong interest in routine use of large (even complete) patient data bases A researchable topic! Priority Medicines Project :  Priority Medicines Project For further questions, please contact: [email protected] [email protected] +41-22-791-4533 http://mednet3.who.int/prioritymeds/report/index.htm

Related presentations


Other presentations created by Alien

Physical Security Lecture
05. 01. 2008
0 views

Physical Security Lecture

GREEK THEATRE
15. 10. 2007
0 views

GREEK THEATRE

Singapore National Symbols
14. 09. 2007
0 views

Singapore National Symbols

Origins of the Cold War
23. 12. 2007
0 views

Origins of the Cold War

CG43SlideSet
30. 04. 2008
0 views

CG43SlideSet

kaiser pres
28. 04. 2008
0 views

kaiser pres

GoldDifferences
22. 04. 2008
0 views

GoldDifferences

visn8
17. 04. 2008
0 views

visn8

dr rom
14. 04. 2008
0 views

dr rom

file 6943
13. 04. 2008
0 views

file 6943

The Peak Oil Context Tom Petrie
10. 04. 2008
0 views

The Peak Oil Context Tom Petrie

H106g
09. 04. 2008
0 views

H106g

JapaneseGeography
07. 04. 2008
0 views

JapaneseGeography

Hamburg 2007
14. 09. 2007
0 views

Hamburg 2007

lfg
14. 09. 2007
0 views

lfg

Eddie Final Presentation
14. 09. 2007
0 views

Eddie Final Presentation

chalmers
14. 09. 2007
0 views

chalmers

The Rain Forest Final
14. 09. 2007
0 views

The Rain Forest Final

ECAKnowledgeFair
12. 10. 2007
0 views

ECAKnowledgeFair

Ch18part1
15. 10. 2007
0 views

Ch18part1

WNV AVB 02212006
21. 10. 2007
0 views

WNV AVB 02212006

giraffe pp
14. 09. 2007
0 views

giraffe pp

giraffe powerpoint
14. 09. 2007
0 views

giraffe powerpoint

giraffe
14. 09. 2007
0 views

giraffe

COOL STUFF ABOUT GIRAFFES
14. 09. 2007
0 views

COOL STUFF ABOUT GIRAFFES

ub041104
23. 10. 2007
0 views

ub041104

STORY OF THEME AND PLOT
23. 10. 2007
0 views

STORY OF THEME AND PLOT

PhiladelphiaZooPPP
14. 09. 2007
0 views

PhiladelphiaZooPPP

qu10 11
01. 12. 2007
0 views

qu10 11

Angelos CME Energetics
02. 11. 2007
0 views

Angelos CME Energetics

pptPanama s
22. 10. 2007
0 views

pptPanama s

hirotani
13. 11. 2007
0 views

hirotani

bon2003 mpls
29. 10. 2007
0 views

bon2003 mpls

PROF AZZA
23. 10. 2007
0 views

PROF AZZA

Fenton
29. 10. 2007
0 views

Fenton

Countering Offshore
29. 12. 2007
0 views

Countering Offshore

walters082902
23. 11. 2007
0 views

walters082902

razbash
26. 11. 2007
0 views

razbash

DVMRPandMOSPF
01. 01. 2008
0 views

DVMRPandMOSPF

One 783Ngupta
04. 01. 2008
0 views

One 783Ngupta

Chapter 18 PPT
22. 10. 2007
0 views

Chapter 18 PPT

History of NAIS John Wiemers
20. 08. 2007
0 views

History of NAIS John Wiemers

BSP2D
14. 09. 2007
0 views

BSP2D

costarica1 ftparraud
22. 10. 2007
0 views

costarica1 ftparraud

mcmc2000a
06. 11. 2007
0 views

mcmc2000a

050317lc
16. 11. 2007
0 views

050317lc

ALA2003 OAI
04. 10. 2007
0 views

ALA2003 OAI

fwing
22. 10. 2007
0 views

fwing

acute 060727 transfusionmed
23. 10. 2007
0 views

acute 060727 transfusionmed

bckexpk3b
09. 07. 2007
0 views

bckexpk3b

anorexia
09. 07. 2007
0 views

anorexia

070207 Adjektiv
09. 07. 2007
0 views

070207 Adjektiv

A Brachmann
09. 10. 2007
0 views

A Brachmann

mueller jun07
19. 10. 2007
0 views

mueller jun07

Late Classic Maya Collapse
16. 02. 2008
0 views

Late Classic Maya Collapse

ISLAS GALAPAGOS
14. 09. 2007
0 views

ISLAS GALAPAGOS

Heatingoilwebsection ppp
24. 02. 2008
0 views

Heatingoilwebsection ppp

PIndustrialTrucks
26. 02. 2008
0 views

PIndustrialTrucks

ethanap
14. 09. 2007
0 views

ethanap

Propulsion CEV
07. 11. 2007
0 views

Propulsion CEV

MichelleWatt
20. 02. 2008
0 views

MichelleWatt

newsletterfall04
11. 03. 2008
0 views

newsletterfall04

EC T9 2008 Conference Proposal
12. 03. 2008
0 views

EC T9 2008 Conference Proposal

drugstatistics
17. 12. 2007
0 views

drugstatistics

icfa chep06
23. 10. 2007
0 views

icfa chep06

Hubert CW8
14. 09. 2007
0 views

Hubert CW8

A mi Papi 2089
19. 06. 2007
0 views

A mi Papi 2089

An ode to Mothers
19. 06. 2007
0 views

An ode to Mothers

LoffPresentation
17. 10. 2007
0 views

LoffPresentation

Maschera
19. 06. 2007
0 views

Maschera

manual
19. 06. 2007
0 views

manual

Luces De Navidad 1848
19. 06. 2007
0 views

Luces De Navidad 1848

leer
19. 06. 2007
0 views

leer

Lean Six SigmaATL011706
19. 06. 2007
0 views

Lean Six SigmaATL011706

lexisnexis
05. 10. 2007
0 views

lexisnexis

OAT Presentation v5
19. 06. 2007
0 views

OAT Presentation v5

moscatelli
19. 06. 2007
0 views

moscatelli

moon split
19. 06. 2007
0 views

moon split

money plus
19. 06. 2007
0 views

money plus

MKCL
19. 06. 2007
0 views

MKCL

Journey of the Spirit Lesson 6
01. 10. 2007
0 views

Journey of the Spirit Lesson 6

2 Jornada BISHOP
10. 10. 2007
0 views

2 Jornada BISHOP

No esperes
19. 06. 2007
0 views

No esperes

Amores locos 1992
19. 06. 2007
0 views

Amores locos 1992

College English book 2 Unit 7
24. 02. 2008
0 views

College English book 2 Unit 7

A vista de pajaro II 2109
19. 06. 2007
0 views

A vista de pajaro II 2109

Ammosov Vladimir ammosov pra
12. 10. 2007
0 views

Ammosov Vladimir ammosov pra

Amber la mejor de todas
19. 06. 2007
0 views

Amber la mejor de todas

CP317 lecture 6 Huck II 05
11. 12. 2007
0 views

CP317 lecture 6 Huck II 05

AHQA031204Mck
09. 07. 2007
0 views

AHQA031204Mck

Evergreen
03. 01. 2008
0 views

Evergreen

04 NJIT3
02. 01. 2008
0 views

04 NJIT3

Poster A4 Glasgow nov04
04. 10. 2007
0 views

Poster A4 Glasgow nov04

Ally McBeal
09. 07. 2007
0 views

Ally McBeal

sara paige
14. 09. 2007
0 views

sara paige

36181003
24. 10. 2007
0 views

36181003

MusicApprecBaroque 2
22. 11. 2007
0 views

MusicApprecBaroque 2

ELE386 Malware
20. 08. 2007
0 views

ELE386 Malware

RohanShah
12. 10. 2007
0 views

RohanShah

1022MAS net big picture
03. 01. 2008
0 views

1022MAS net big picture

Lo Suficiente 1744
19. 06. 2007
0 views

Lo Suficiente 1744

gm3 jp item14 Mangrove ITTO
22. 10. 2007
0 views

gm3 jp item14 Mangrove ITTO

2005AuditResults
09. 07. 2007
0 views

2005AuditResults

HABIC1 summary
17. 11. 2007
0 views

HABIC1 summary

aro ald informalsession
24. 10. 2007
0 views

aro ald informalsession

etu ambassadeurs juin 07 en
13. 03. 2008
0 views

etu ambassadeurs juin 07 en

Gobert poster
03. 10. 2007
0 views

Gobert poster

Kistenev
15. 11. 2007
0 views

Kistenev

6 History of Chemistry I
12. 10. 2007
0 views

6 History of Chemistry I

Jan2000report
04. 01. 2008
0 views

Jan2000report

course 4
03. 01. 2008
0 views

course 4